C4 Therapeutics, Inc. Insider Trading Activity

C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.

Rhea-AI Filing Summary

C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.

Key details of the stock option:

• The option expires on June 17, 2035
• Vesting occurs at the earlier of June 18, 2026 or the next annual stockholders' meeting
• Vesting is contingent on continued Board service
• The grant was reported via Form 4 filing, indicating changes in beneficial ownership

This equity compensation aligns with standard director compensation practices and serves to align the director's interests with shareholders. The relatively low exercise price reflects the company's current market conditions.

Insider Trade Summary

Grant/Award: 35,500 shares

Grant/Award 1 txn

Insider Hoerter Steven L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	35,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 35,500 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did C4 Therapeutics (CCCC) director Steven Hoerter receive on June 18, 2025?

Steven Hoerter received 35,500 stock options with an exercise price of $1.44 per share. These options were granted on June 18, 2025, and expire on June 17, 2035.

What are the vesting terms for CCCC director Steven Hoerter's June 2025 stock options?

The stock options will vest in full upon the earlier of: (i) June 18, 2026, or (ii) C4 Therapeutics' next annual stockholder meeting, subject to Hoerter's continued service as a Board member on such date.

How many shares of CCCC can Steven Hoerter purchase with his new stock options?

Steven Hoerter can purchase 35,500 shares of C4 Therapeutics common stock through these stock options at an exercise price of $1.44 per share.

When do Steven Hoerter's CCCC stock options from June 2025 expire?

The stock options expire on June 17, 2035, which is approximately 10 years from the grant date of June 18, 2025.

What is Steven Hoerter's role at C4 Therapeutics (CCCC)?

Steven Hoerter serves as a Director on the Board of C4 Therapeutics, as indicated by the 'X' marked under the Director category in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoerter Steven L.

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.44	06/18/2025		A		35,500		(1)	06/17/2035	Common Stock	35,500	$0	35,500	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Jolie M. Siegel, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.